Ophthalmic drugs have now become a golden track for new drug research and development, and in recent years, the domestic ophthalmic drug market has maintained steady growth
.
According to statistics, in 2021, the sales scale of China's ophthalmic medicine hospital market has reached 9.
2 billion yuan, a year-on-year increase of 22%, and the current sales of H1 in 2022 have nearly 3 billion yuan, and higher than the same period last year, according to this growth trend, it is expected to exceed the 10 billion yuan mark
in 2022.
At present, in the context of strong market demand and huge prospects in the domestic ophthalmic drug market, domestic pharmaceutical companies are also constantly joining this track
.
It is worth mentioning that with continuous investment, there is good news for related companies recently
.
On November 24, Kanghong Pharmaceutical announced that KH631 ophthalmic injection was approved for clinical trials in the United States for the treatment of neovascular (wet) age-related macular degeneration
.
It is understood that KH631 ophthalmic injection is a new class 1 new drug for therapeutic biological products with independent intellectual property rights for the treatment of neovascular (wet) age-related macular degeneration by adeno-associated virus delivery of target genes
.
On November 15, 2022, the above-mentioned new drugs have obtained the notification of clinical trial approval from the China Medical Products Administration (NMPA) and agreed to carry out clinical trials
.
After the approval of clinical trials in the United States, Kanghong Pharmaceutical said that it will carry out follow-up work
in accordance with the relevant regulations and requirements of US drug registration according to the actual situation.
This follows Zhaoke Ophthalmology announced that it has entered into an exclusive distribution agreement
for TONO-i in Greater China with South Korean company C&V Tech.
Zhaoke Ophthalmology said that TONO-i will be an important part of the company's glaucoma medical product portfolio to fill the demand gap
of low diagnosis and treatment rates in China.
In addition, on November 10, the Class 5.
1 new drug levofloxacin dexamethasone eye drops introduced by Zhaoke Ophthalmology was also declared for marketing
in China.
This is an innovative drug with the development code NTC010 introduced by the company from NTC, which is intended to be developed for the prevention and treatment of inflammation and infection
after cataract surgery.
The drug has been approved for marketing
overseas.
On October 28, Zhaoke Ophthalmology also announced that partner Vyluma announced the positive results
of the phase III CHAMP study of NVK002 for myopia progression in children.
It is understood that NVK002 is a new topical eye solution for controlling the progression of myopia in children and adolescents (3 to 17 years old), which can successfully solve the instability of low-concentration atropine, and the product does not contain preservatives, and the expected shelf life is more than 24 months
.
In general, driven by the popularization of electronic products and the aging of the population, the domestic ophthalmic market will continue to grow, and the industry development space will become more and more broad
.
The industry expects that affected by this, the enthusiasm of related enterprises for research and development will continue to rise, and the results will continue to emerge
.
However, it is worth noting that on the whole, the progress of basic research related to ophthalmic diseases is slow, and China mainly focuses on new processes and new dosage forms in the research and development of drugs, while the indications are mainly concentrated in glaucoma and high intraocular pressure
.
Therefore, in the future, relevant enterprises still need to accelerate
the exploration and innovation of new targets.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
